Osivax
Created in 2017
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
5,227Global tags
Activities
Technologies
Entity types
Location
70 Rue Saint-Jean-de-Dieu, 69007 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 53
SIREN
829604750Engaged corporates
22
11 13Added in Motherbase
1 year, 10 months ago
biotech Value proposition
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
biotechnology, immunology, antigens, vaccine, Influenza, universal, cellular immune response, CD8 T-cell, Infectious diseases, Immuno-oncology, and covidOriginal language
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
HOME - Osivax
Osivax is developing a new class of universal vaccines empowering both arms of the immune system.
https://osivax.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 10 Apr 2024 | | |
 | Gouvernement | Other 14 Feb 2024 | | |
 BNP Paribas Bank, Banking | BNP Paribas Bank, Banking | Other 21 Oct 2023 | | |
 Elsevier Publishing, IT Services and IT Consulting | Elsevier Publishing, IT Services and IT Consulting | Other 29 Sep 2023 | | |
 Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Other 30 Oct 2023 | | |
 Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Other 31 Aug 2023 | | |
 La French Tech Alpes Government Administration, French Tech | La French Tech Alpes Government Administration, French Tech | Other 31 Mar 2023 | | |
 Anaxago Startup accelerator & VC, Venture Capital and Private Equity Principals | Anaxago Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 30 Jul 2023 | | |
 EIT - European Institute of Innovation and Technology European Union, Government Administration | EIT - European Institute of Innovation and Technology European Union, Government Administration | Other 19 Jun 2023 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 1 Apr 2023 | | |